Peaches Biotech ready to enter into the production of biological medicines with the Histokine factory
The Madrid-based laboratory, together with Histocell and Cardiva, has launched Histokine, located in the Basque Country (Spain). It is the first GMP-certified plant approved by a regulator to manufacture secretomes.
Peaches Biotech creates its own factory to produce its secretome platform, a type of advanced therapy. The new facility is Histokine, a joint venture between the Madrid-based company and Histocell together with Cardiva. It is also the first plant of its kind to be authorised by a regulatory system with "Good Manufacturing Practices" certification.
Histokine is located in Bilbao (Basque Country) and has had the green four months ago. Specifically, it is an extension of the Histocell plant. It was created to serve the needs of Peaches Biotech in the clinical trial phases of its new biomedicines and the subsequent requirements for international distribution and marketing.
This alliance is based on the specificity of the product, as it is a selective secretome, a new product at industrial level for which there are still no plants in Spain for its manufacture.
Peaches and Cardiva have invested four million euros to set up the alliance. The medical device distributor acts as a financial partner in the development of the factory. Histocell has provided the human and technical equipment, valued at another four million. Histokine currently employs 40 people.
Up to 25 treatments
Peaches Biotech has invested almost 20 million in the development of its secretome platform created from cell co-culture. This is a new model based on a therapeutic concept that represents the evolution of stem cell therapies. This concept collects the chemical commands that the stem cell emits to a damaged tissue to enable its regeneration. "These orders are what we isolate and convert them into drugs," says the company's CEO, Juan Carlos de Gregorio.
Up to 25 different drugs will be produced from this platform. All will be manufactured with the same technology - cell co-culture - and each will have a different secretome. In addition, they will be hospital treatments.
Currently, Peaches is developing an anti-inflammatory therapy. This will be the first to reach the market. The target date for commercialisation is 2026. The next to be launched on the market will be a muscle regenerator, a tendon regenerator and a nerve regenerator.